{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:09:12Z","timestamp":1785431352935,"version":"3.56.0"},"reference-count":82,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Heart failure (HF) continues to challenge clinicians worldwide, not only because of its high morbidity and mortality but also due to the persistent difficulty in translating therapeutic advances into routine care. Despite the availability of effective treatments, data show striking gaps in the optimal use of guideline-directed medical therapy. Among the four pillars of guideline-directed medical therapy, mineralocorticoid receptor antagonists (MRAs) remain the least prescribed. This underuse is concerning considering the evidence demonstrating consistent benefits of MRAs across different HF phenotypes. In this review, we revisit the role of MRAs across the spectrum of HF. We summarise the supporting evidence, discuss their mechanisms of action and provide practical guidance on patient eligibility and initiation strategies. In addition, we address common barriers that often limit their use. By combining mechanistic insights, trial evidence and pragmatic recommendations, this review aims to facilitate broader and earlier use of MRAs, thereby helping to close a major gap in the implementation of evidence-based HF care.<\/jats:p>","DOI":"10.15420\/cfr.2025.57","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:37:18Z","timestamp":1781260638000},"source":"Crossref","is-referenced-by-count":0,"title":["Mineralocorticoid Receptor Antagonist Use in Contemporary Heart Failure Care"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6356-2284","authenticated-orcid":false,"given":"Jolie","family":"Bruno","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04q1vy171","id-type":"ROR","asserted-by":"publisher"}],"name":"Marqueurs cardiovasculaires en situation de stress"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-7753","authenticated-orcid":false,"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04q1vy171","id-type":"ROR","asserted-by":"publisher"}],"name":"Marqueurs cardiovasculaires en situation de stress"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-322X","authenticated-orcid":false,"given":"L\u00eddia Zytynski","family":"Moura","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02x1vjk79","id-type":"ROR","asserted-by":"publisher"}],"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-9274","authenticated-orcid":false,"given":"Jelena","family":"\u010celutkien\u0117","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03nadee84","id-type":"ROR","asserted-by":"publisher"}],"name":"Vilnius University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-805X","authenticated-orcid":false,"given":"Andrew","family":"Sindone","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0384j8v12","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-2263","authenticated-orcid":false,"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/039zxt351","id-type":"ROR","asserted-by":"publisher"}],"name":"IRCCS Ospedale San Raffaele"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Savarese G, Kishi T, Vardeny O, et al. Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail 2023;11:1\u201314. https:\/\/doi.org\/10.1016\/j.jchf.2022.08.009; PMID: 36202739. DOI: 10.1016\/j.jchf.2022.08.009","DOI":"10.1016\/j.jchf.2022.08.009"},{"key":"ref1","unstructured":"Malgie J, Wilde MI, Clephas PRD, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study. Eur J Heart Fail 2024;26:1549\u201360. https:\/\/doi.org\/10.1002\/ejhf.3267; PMID: 38734980."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Savarese G, Adamsson Eryd S, et al. Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF. JACC Heart Fail 2023;11:1320\u201332. https:\/\/doi.org\/10.1016\/j.jchf.2023.04.017; PMID: 37354145. DOI: 10.1016\/j.jchf.2023.04.017","DOI":"10.1016\/j.jchf.2023.04.017"},{"key":"ref3","unstructured":"Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070; PMID: 30025570."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Anderson L, Bayes-Genis A, Bodeg\u00e5rd J, et al. Suspected de novo heart failure in outpatient care: the REVOLUTION HF study. Eur Heart J 2025;46:1493\u2013503. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf034; PMID: 39935142. DOI: 10.1093\/eurheartj\/ehaf034","DOI":"10.1093\/eurheartj\/ehaf034"},{"key":"ref5","unstructured":"G-CHF Investigators, Joseph P, Roy A, et al. Global variations in heart failure etiology, management, and outcomes. JAMA 2023;329:1650\u201361. https:\/\/doi.org\/10.1001\/jama.2023.5942; PMID: 37191704."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"De Albuquerque DC, De Barros E Silva PGM, Lopes RD, et al. In-hospital management and long-term clinical outcomes and adherence in patients with acute decompensated heart failure: primary results of the first Brazilian registry of heart failure (BREATHE). J Card Fail 2024;30:639\u201350. https:\/\/doi.org\/10.1016\/j.cardfail.2023.08.014; PMID: 37648061. DOI: 10.1016\/j.cardfail.2023.08.014","DOI":"10.1016\/j.cardfail.2023.08.014"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Greene SJ, Bash LD, Tebbs KW, et al. Physician-reported reasons for not initiating guideline-directed medical therapy for heart failure. JACC Heart Fail 2024;12:2120\u20132. https:\/\/doi.org\/10.1016\/j.jchf.2024.08.002; PMID: 39297863. DOI: 10.1016\/j.jchf.2024.08.002","DOI":"10.1016\/j.jchf.2024.08.002"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001; PMID: 10471456. DOI: 10.1056\/NEJM199909023411001","DOI":"10.1056\/NEJM199909023411001"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309\u201321. https:\/\/doi.org\/10.1056\/NEJMoa030207; PMID: 12668699. DOI: 10.1056\/NEJMoa030207","DOI":"10.1056\/NEJMoa030207"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492; PMID: 21073363. DOI: 10.1056\/NEJMoa1009492","DOI":"10.1056\/NEJMoa1009492"},{"key":"ref11","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731; PMID: 24716680."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Beldhuis IE, Myhre PL, Bristow M, et al. Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function. J Am Coll Cardiol 2021;77:1211\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.057; PMID: 33663739. DOI: 10.1016\/j.jacc.2020.12.057","DOI":"10.1016\/j.jacc.2020.12.057"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107; PMID: 39225278. DOI: 10.1056\/NEJMe2410904","DOI":"10.1056\/NEJMe2410904"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u20131032. https:\/\/doi.org\/10.1161\/cir.0000000000001063; PMID: 35363499. DOI: 10.1161\/CIR.0000000000001073","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref15","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195; PMID: 37622666."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013;309:781\u201391. https:\/\/doi.org\/10.1001\/jama.2013.905; PMID: 23443441. DOI: 10.1001\/jama.2013.905","DOI":"10.1001\/jama.2013.905"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Cleland JG, Girerd N, et al. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Eur J Heart Fail 2023;25:108\u201313. https:\/\/doi.org\/10.1002\/ejhf.2726; PMID: 36303266. DOI: 10.1002\/ejhf.2726","DOI":"10.1002\/ejhf.2726"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 2016;37:2105\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132; PMID: 27130705. DOI: 10.1093\/eurheartj\/ehw132","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"ref19","unstructured":"Rossignol P, Zannad F, Massy Z, et al. Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis. Lancet 2025;406:705\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(25)01194-8; PMID: 40818851."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol 2017;2:950\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2017.2198; PMID: 28700781. DOI: 10.1001\/jamacardio.2017.2198","DOI":"10.1001\/jamacardio.2017.2198"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Yaku H, Kato T, Morimoto T, et al. Association of mineralocorticoid receptor antagonist use with all-cause mortality and hospital readmission in older adults with acute decompensated heart failure. JAMA Netw Open 2019;2:e195892. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.5892; PMID: 31225889. DOI: 10.1001\/jamanetworkopen.2019.5892","DOI":"10.1001\/jamanetworkopen.2019.5892"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Beldhuis IE, Damman K, Pang PS, et al. Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure. Eur J Heart Fail 2023;25:1584\u201392. https:\/\/doi.org\/10.1002\/ejhf.2975; PMID: 37462255. DOI: 10.1002\/ejhf.2975","DOI":"10.1002\/ejhf.2975"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Yamashina A, Satomi K, et al. Adverse events associated with early initiation of eplerenone in patients hospitalized for acute heart failure. Int J Cardiol 2024;415:132477. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132477; PMID: 39181408. DOI: 10.1016\/j.ijcard.2024.132477","DOI":"10.1016\/j.ijcard.2024.132477"},{"key":"ref24","unstructured":"Beygui F, Cayla C, Roule V, et al. Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J Am Coll Cardiol 2016;67:1917\u201327. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.033; PMID: 27102506."},{"key":"ref25","unstructured":"Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. Eur Heart J 2014;35:2295\u2013302. https:\/\/doi.org\/10.1093\/eurheartj\/ehu164; PMID: 24780614."},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Jolly SS, d\u2019Entremont M-A, Pitt B, et al. Routine spironolactone in acute myocardial infarction. N Engl J Med 2025;392:643\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2405923; PMID: 39555814. DOI: 10.1056\/NEJMe2414472","DOI":"10.1056\/NEJMe2414472"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34:2453\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/eht187; PMID: 23713082. DOI: 10.1093\/eurheartj\/eht187","DOI":"10.1093\/eurheartj\/eht187"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015;314:884\u201394. https:\/\/doi.org\/10.1001\/jama.2015.10081; PMID: 26325557. DOI: 10.1001\/jama.2015.10081","DOI":"10.1001\/jama.2015.10081"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Agarwal R, Green JB, Heerspink HJL, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med 2025;393:533\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2410659; PMID: 40470996. DOI: 10.1056\/NEJMoa2410659","DOI":"10.1056\/NEJMoa2410659"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021;385:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956; PMID: 34449181. DOI: 10.1056\/NEJMoa2110956","DOI":"10.1056\/NEJMoa2110956"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845; PMID: 33264825. DOI: 10.1056\/NEJMoa2025845","DOI":"10.1056\/NEJMoa2025845"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the Figaro-DKD trial. Circulation 2022;145:437\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983; PMID: 34775784. DOI: 10.1161\/CIRCULATIONAHA.121.057983","DOI":"10.1161\/CIRCULATIONAHA.121.057983"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Elshahat A, Mansour A, Ellabban M, et al. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2024;24:489. https:\/\/doi.org\/10.1186\/s12872-024-04103-7; PMID: 39271992. DOI: 10.1186\/s12872-024-04103-7","DOI":"10.1186\/s12872-024-04103-7"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Elshahat A, Abdelaziz A, Mansour A, et al. Eplerenone vs spironolactone and cardiac remodeling in heart failure with reduced ejection fraction: a meta-analysis. Mayo Clin Proc 2025;100:572\u20136. https:\/\/doi.org\/10.1016\/j.mayocp.2024.11.009; PMID: 40044367. DOI: 10.1016\/j.mayocp.2024.11.009","DOI":"10.1016\/j.mayocp.2024.11.009"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 2024;404:1119\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(24)01733-1; PMID: 39232490. DOI: 10.1016\/S0140-6736(24)01733-1","DOI":"10.1016\/S0140-6736(24)01733-1"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Wang J, Zheng M, Yang Y, et al. Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases. ESC Heart Fail 2025;12:3062\u201372. https:\/\/doi.org\/10.1002\/ehf2.15329; PMID: 40368329. DOI: 10.1002\/ehf2.15329","DOI":"10.1002\/ehf2.15329"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Girerd N, Zannad F. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Nephrol Dial Transplant 2024;39:1063\u201372. https:\/\/doi.org\/10.1093\/ndt\/gfae004; PMID: 38192033. DOI: 10.1093\/ndt\/gfae004","DOI":"10.1093\/ndt\/gfae004"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Pandey AK, Bhatt DL, Cosentino F, et al. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J 2022;43:2931\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehac299; PMID: 35713973. DOI: 10.1093\/eurheartj\/ehac299","DOI":"10.1093\/eurheartj\/ehac299"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist. Front Cardiovasc Med 2024;11:1476029. https:\/\/doi.org\/10.3389\/fcvm.2024.1476029; PMID: 39376623. DOI: 10.3389\/fcvm.2024.1476029","DOI":"10.3389\/fcvm.2024.1476029"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol 2016;27:78\u201385. https:\/\/doi.org\/10.1016\/j.coph.2016.02.005; PMID: 26939027. DOI: 10.1016\/j.coph.2016.02.005","DOI":"10.1016\/j.coph.2016.02.005"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Seferovic PM, Pelliccia F, Zivkovic I, et al. Mineralocorticoid receptor antagonists, a class beyond spironolactone \u2014 focus on the special pharmacologic properties of eplerenone. Int J Cardiol 2015;200:3\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.096; PMID: 26404746. DOI: 10.1016\/j.ijcard.2015.02.096","DOI":"10.1016\/j.ijcard.2015.02.096"},{"key":"ref42","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID: 34447992."},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Taub PR, Greene SJ, Fudim M. The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment. Heart Fail Rev 2025;30:971\u201384. https:\/\/doi.org\/10.1007\/s10741-025-10520-3; PMID: 40448875. DOI: 10.1007\/s10741-025-10520-3","DOI":"10.1007\/s10741-025-10520-3"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Banerjee M, Maisnam I, Pal R, Mukhopadhyay S. Mineralocorticoid receptor antagonists with sodium\u2013glucose co-transporter-2 inhibitors in heart failure: a meta-analysis. Eur Heart J 2023;44:3686\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehad522; PMID: 37605637. DOI: 10.1093\/eurheartj\/ehad522","DOI":"10.1093\/eurheartj\/ehad522"},{"key":"ref45","unstructured":"Vaduganathan M, Claggett BL, Kulac IJ, et al. Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Circulation 2025;151:149\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072055; PMID: 39340828."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Verma S, Dhingra NK, Pandey AK, Cosentino F. Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure. Eur Heart J 2022;43:2994\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehac304; PMID: 35680380. DOI: 10.1093\/eurheartj\/ehac304","DOI":"10.1093\/eurheartj\/ehac304"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Zannad F, Butler J, et al. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J 2022;43:2984\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehac306; PMID: 35687107. DOI: 10.1093\/eurheartj\/ehac306","DOI":"10.1093\/eurheartj\/ehac306"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Rosano GMC, Teerlink JR, Kinugawa K, et al. The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS). Eur J Heart Fail 2025;27:1174\u201387. https:\/\/doi.org\/10.1002\/ejhf.3646; PMID: 40260636. DOI: 10.1002\/ejhf.3646 DOI: 10.1016\/j.cardfail.2025.03.014","DOI":"10.1002\/ejhf.3646"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Bruno J, Grundtvig Skaarup K, Mebazaa A. Guideline-based preventive management in metabolic and renal disease: a paradigm shift for all healthcare professionals to maintain \u201cnormal\u201d cardiac function. Eur Heart J 2025:ehaf681. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf681; PMID: 40879682. DOI: 10.1093\/eurheartj\/ehaf681","DOI":"10.1093\/eurheartj\/ehaf681"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1; PMID: 36356631. DOI: 10.1016\/S0140-6736(22)02076-1","DOI":"10.1016\/S0140-6736(22)02076-1"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Gomez KA, Tromp J, Figarska SM, et al. Distinct comorbidity clusters in patients with acute heart failure: data from RELAX-AHF-2. JACC Heart Fail 2024;12:1762\u201374. https:\/\/doi.org\/10.1016\/j.jchf.2024.04.028; PMID: 38970586. DOI: 10.1016\/j.jchf.2024.04.028","DOI":"10.1016\/j.jchf.2024.04.028"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Anker SD, Usman MS, Anker MS, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail 2023;25:936\u201355. https:\/\/doi.org\/10.1002\/ejhf.2894; PMID: 37461163. DOI: 10.1002\/ejhf.2894","DOI":"10.1002\/ejhf.2894"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Chioncel O, Benson L, Crespo-Leiro MG, et al. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry. Eur J Prev Cardiol 2023;30:1346\u201358. https:\/\/doi.org\/10.1093\/eurjpc\/zwad151; PMID: 37172316. DOI: 10.1093\/eurjpc\/zwad151","DOI":"10.1093\/eurjpc\/zwad151"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion \u2014 a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137\u201355. https:\/\/doi.org\/10.1002\/ejhf.1369; PMID: 30600580. DOI: 10.1002\/ejhf.1477","DOI":"10.1002\/ejhf.1477"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Cox ZL, Testani JM. Loop diuretic resistance complicating acute heart failure. Heart Fail Rev 2020;25:133\u201345. https:\/\/doi.org\/10.1007\/s10741-019-09851-9; PMID: 31520280. DOI: 10.1007\/s10741-019-09851-9","DOI":"10.1007\/s10741-019-09851-9"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bruno J, Spahillari A, Mebazaa A. Toward a streamlined optimization protocol for patients with heart failure with reduced ejection fraction: emerging evidence. JACC Heart Fail 2026;14:102724. https:\/\/doi.org\/10.1016\/j.jchf.2025.102724; PMID: 41148072. DOI: 10.1016\/j.jchf.2025.102724","DOI":"10.1016\/j.jchf.2025.102724"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"De P, Khine MT, Frankel A, et al. Finerenone in the management of diabetes kidney disease. BMC Nephrol 2025;26:63. https:\/\/doi.org\/10.1186\/s12882-025-03985-9; PMID: 39923037. DOI: 10.1186\/s12882-025-03985-9","DOI":"10.1186\/s12882-025-03985-9"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Dawadi S, Shrestha DB, Oli PR, et al. Mineralocorticoid receptor antagonist versus placebo in a patient with end-stage kidney disease under renal replacement therapy: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2025;85:270\u20137. https:\/\/doi.org\/10.1097\/FJC.0000000000001661; PMID: 39665433. DOI: 10.1097\/FJC.0000000000001661","DOI":"10.1097\/FJC.0000000000001661"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lin DSH, Lin FJ, Lin YS, et al. The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure. Eur J Heart Fail 2023;25:98\u2013107. https:\/\/doi.org\/10.1002\/ejhf.2740; PMID: 36404402. DOI: 10.1002\/ejhf.2740","DOI":"10.1002\/ejhf.2740"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Pitt B, Zannad F. Mineralocorticoid receptor antagonists in heart failure: an update. Circ Heart Fail 2024;17:e011629. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.011629; PMID: 39584253. DOI: 10.1161\/CIRCHEARTFAILURE.124.011629","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart failure: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2836\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.021; PMID: 32498812. DOI: 10.1016\/j.jacc.2020.04.021","DOI":"10.1016\/j.jacc.2020.04.021"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Trevisan M, De Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 2018;20:1217\u201326. https:\/\/doi.org\/10.1002\/ejhf.1199; PMID: 29667759. DOI: 10.1002\/ejhf.1199 DOI: 10.1002\/ejhf.1367","DOI":"10.1002\/ejhf.1199"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"AlSahow A. Moderate stepwise restriction of potassium intake to reduce risk of hyperkalemia in chronic kidney disease: a literature review. World J Nephrol 2023;12:73\u201381. https:\/\/doi.org\/10.5527\/wjn.v12.i4.73; PMID: 37766841. DOI: 10.5527\/wjn.v12.i4.73","DOI":"10.5527\/wjn.v12.i4.73"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Grobbee DE, Filippatos G, Desai NR, et al. Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Fail 2024;11:1821\u201340. https:\/\/doi.org\/10.1002\/ehf2.14661; PMID: 38439165. DOI: 10.1002\/ehf2.14661","DOI":"10.1002\/ehf2.14661"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Zhou J, Jin X, Zhou J, et al. Clinical outcomes by serum potassium levels for patients hospitalized for heart failure: secondary analysis of data from the China National Heart Failure Registry. Clin Cardiol 2023;46:1345\u201352. https:\/\/doi.org\/10.1002\/clc.24114; PMID: 37577821. DOI: 10.1002\/clc.24114","DOI":"10.1002\/clc.24114"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Rossignol P, Lainscak M, Crespo-Leiro MG, et al. Unravelling the interplay between hyperkalaemia, renin\u2013angiotensin\u2013aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020;22:1378\u201389. https:\/\/doi.org\/10.1002\/ejhf.1793; PMID: 32243669. DOI: 10.1002\/ejhf.1793","DOI":"10.1002\/ejhf.1793"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Matsumoto S, Henderson AD, Shen L, et al. Mineralocorticoid receptor antagonists in patients with heart failure and impaired renal function. J Am Coll Cardiol 2024;83:2426\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.426; PMID: 38739064. DOI: 10.1016\/j.jacc.2024.03.426","DOI":"10.1016\/j.jacc.2024.03.426"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Abuelazm M, Badr A, Turkmani M, et al. The efficacy and safety of new potassium binders on renin\u2013angiotensin\u2013aldosterone system inhibitor optimization in heart failure patients: a systematic review and meta-analysis. ESC Heart Fail 2024;11:28\u201343. https:\/\/doi.org\/10.1002\/ehf2.14588; PMID: 38012095. DOI: 10.1002\/ehf2.14588","DOI":"10.1002\/ehf2.14588"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Masi S, Dalpiaz H, Piludu S, et al. New strategies for the treatment of hyperkalemia. Eur J Intern Med 2025;132:18\u201326. https:\/\/doi.org\/10.1016\/j.ejim.2024.10.016; PMID: 39489630. DOI: 10.1016\/j.ejim.2024.10.016","DOI":"10.1016\/j.ejim.2024.10.016"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Yu W, Luo F, Rao J, et al. Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis. Front Cardiovasc Med 2025;12:1601552. https:\/\/doi.org\/10.3389\/fcvm.2025.1601552; PMID: 40495987. DOI: 10.3389\/fcvm.2025.1652440","DOI":"10.3389\/fcvm.2025.1652440"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Pitt B, Ferreira JP, et al. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease. Eur Heart J 2025;46:2618\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf225; PMID: 40214750. DOI: 10.1093\/eurheartj\/ehaf225","DOI":"10.1093\/eurheartj\/ehaf225"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Serenelli M, Jackson A, Dewan P, et al. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail 2020;8:188\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.011; PMID: 31926854. DOI: 10.1016\/j.jchf.2019.09.011","DOI":"10.1016\/j.jchf.2019.09.011"},{"key":"ref73","unstructured":"Balthazar T, Raes M, Carmeliet T, et al. Aggressive up-titration of heart failure guideline-directed medical therapies in cardiogenic shock supported by a percutaneous ventricular assist device. J Card Fail 2025:S1071-9164(25)00200-3. https:\/\/doi.org\/10.1016\/j.cardfail.2025.04.006; PMID: 40324713."},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Abe T, Jujo K, Kametani M, et al. Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients. ESC Heart Fail 2020;7:2711\u201324. https:\/\/doi.org\/10.1002\/ehf2.12862; PMID: 32860346. DOI: 10.1002\/ehf2.12862","DOI":"10.1002\/ehf2.12862"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Japp D, Shah A, Fisken S, et al. Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis. Age Ageing 2017;46:18\u201325. https:\/\/doi.org\/10.1093\/ageing\/afw138; PMID: 28181634. DOI: 10.1093\/ageing\/afw138","DOI":"10.1093\/ageing\/afw138"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Koeche C, Nogueira ACC, Amaral GPDS, et al. Cost-effectiveness of mineralocorticoid receptor antagonists in ischemic and nonischemic heart failure with reduced ejection fraction: perspective from a universal healthcare system. Value Health Reg Issues 2025;47:101084. https:\/\/doi.org\/10.1016\/j.vhri.2025.101084; PMID: 39946962. DOI: 10.1016\/j.vhri.2025.101084","DOI":"10.1016\/j.vhri.2025.101084"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Dixit NM, Truong KP, Vaduganathan M, et al. Cost-effectiveness of medical therapy for heart failure with mildly reduced and preserved ejection fraction. JACC Heart Fail 2024;12:1226\u201337. https:\/\/doi.org\/10.1016\/j.jchf.2024.03.006; PMID: 38703159. DOI: 10.1016\/j.jchf.2024.03.006","DOI":"10.1016\/j.jchf.2024.03.006"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"McKenna C, Walker S, Lorgelly P, et al. Cost-effectiveness of aldosterone antagonists for the treatment of post\u2013myocardial infarction heart failure. Value Health 2012;15:420\u20138. https:\/\/doi.org\/10.1016\/j.jval.2012.01.004; PMID: 22583451. DOI: 10.1016\/j.jval.2012.01.004","DOI":"10.1016\/j.jval.2012.01.004"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Zheng C, Wu J, Li N, et al. Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States. Diabetes Obes Metab 2025;27:165\u201373. https:\/\/doi.org\/10.1111\/dom.15997; PMID: 39377137. DOI: 10.1111\/dom.15997","DOI":"10.1111\/dom.15997"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Mobaraki H, Azami-Aghdash S, Sarabi Asiabar A, et al. Cost-effectiveness of Eplerenone in treatment of cardiovascular diseases: a systematic review. Med J Islam Repub Iran 2017;31:4. https:\/\/doi.org\/10.18869\/mjiri.31.4; PMID: 28638811. DOI: 10.18869\/mjiri.31.4","DOI":"10.18869\/mjiri.31.4"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Thanh NX, Ezekowitz JA, Tran DT, Kaul P. Cost effectiveness of eplerenone for the treatment of systolic heart failure with mild symptoms in Alberta, Canada. Am J Cardiovasc Drugs 2016;16:365\u201376. https:\/\/doi.org\/10.1007\/s40256-016-0177-0; PMID: 27300508. DOI: 10.1007\/s40256-016-0177-0","DOI":"10.1007\/s40256-016-0177-0"}],"container-title":["Cardiac Failure Review"],"original-title":[],"link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.57","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:26:42Z","timestamp":1781605602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2025.57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":82,"URL":"https:\/\/doi.org\/10.15420\/cfr.2025.57","relation":{},"ISSN":["2057-7540","2057-7559"],"issn-type":[{"value":"2057-7540","type":"print"},{"value":"2057-7559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"e15"}}